Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 13/20 | 0.64 |
| ▸ | NPC1 | O15118 | 12/20 | 0.64 |
| ▸ | RAB9A | P51151 | 12/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.64 |
| ▸ | HPGD | P15428 | 9/20 | 0.64 |
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.64 |
| ▸ | TP53 | P04637 | 6/20 | 0.64 |
| ▸ | GFER | P55789 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 3/20 | 0.64 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 7/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3842984 | 0.89 | SMN1; SMN2 (0.64) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL1789360 | 0.89 | RAB9A (0.60) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL15701353 | 0.86 | RAB9A (0.50) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL5952231 | 0.84 | NPC1 (0.58) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL22488748 | 0.80 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL15520289 | 0.79 | HPSE (0.57) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL222131 | 0.79 | ALDH1A1 (1.00) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL1787551 | 0.78 | HPSE (0.66) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| Fluoride SCHEMBL31379729 | 0.78 | ALDH1A1 (0.96) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| Methane SCHEMBL28366167 | 0.78 | ALDH1A1 (0.96) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | claimed |
| EP-1797072-A4 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-09-09 | — | — | EP | claimed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | claimed |
| EP-1797072-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-06-20 | — | — | EP | claimed |
| WO-2006033943-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2006-03-30 | — | — | WO | claimed |
| EP-2139484-B9 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2139483-B9 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-8710038-B2 | Pyrazole kinase modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2139483-B1 | COMBINATION THERAPIES COMPRISING A QUINOXALINE INHIBITOR OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8513266-B2 | Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha | EXELIXIS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2139484-B1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF PI3K ALPHA | EXELIXIS INC (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| EP-1797072-A4 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1797072-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006033943-A2 | PYRAZOLE KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | SMN1; SMN2 3323/4885NPC1 1639/4885RAB9A 2198/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | SMN1; SMN2 4213/4885NPC1 3142/4885RAB9A 1675/4885 |
| US-20070293507-A1 | Pyrazole Kinase Modulators And Methods Of Use | MAP3K1, MAP3K3, MAP3K5 | SMN1; SMN2 4604/4885NPC1 2422/4885RAB9A 2493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.